Figure 2 | Scientific Reports

Figure 2

From: Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel

Figure 2

Drugs more cytotoxic towards CREB3L1-deficient HCC1806 cells (blue) as compared to CREB3L1 re-expressing HCC1806 + HACREB3L1 cells (black). Cells were plated and after 24 h were treated with the indicated concentration of drug, or solvent control, for 4 days. Solvents (max 0.4%) had little or no effect on the cell growth/number. Cells were stained, imaged and counted. Cell viability (%) was calculated as (# live cells in experimental well)/(# live cells in solvent control well)*100. Mean % viability ± SEM from triplicate measurements from at least 3 independent experiments. (a) Palbociclib Isethionate, 1:3 serial dilutions for concentrations 0–50 μM. (b) Cladribine, 1:3 serial dilutions for concentrations 0–9 μM. (c) Lanatoside C, 1:2 serial dilutions for concentrations 0–2 μM. (d) Homoharringtonine, 1:3 serial dilutions for concentrations 0–333 nM.

Back to article page